MONTE ROSA THERAPEUTICS INC (GLUE)
US61225M1027 - Common Stock
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference ...
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis
The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders ...
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders...
GLUE Crosses Below Key Moving Average Level
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences...
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study...
Commit To Purchase Monte Rosa Therapeutics At $2.50, Earn 18.5% Annualized Using Options
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Monte Rosa Therapeutics (NASDAQ:GLUE) just reported results for the second quar...
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update...
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day ...
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 ...
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis...
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics Announces Leadership Team Promotions
Monte Rosa Therapeutics Becomes Oversold (GLUE)
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 ...
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants ...